UCB announced today that it had successfully completed the European Mutual Recognition Procedure (MRP) for Equasym™ XL for use in the treatment of the symptoms of attention deficit hyperactivity disorder (ADHD) with the UK acting as the Reference Member State for the MRP. All concerned member states endorsed the summary of product characteristics. The national marketing authorizations are expected to be issued over the coming months. Equasym™ XL was launched in the UK, the first European market in 2005.
